08:08 AM EDT, 06/09/2026 (MT Newswires) -- TG Therapeutics ( TGTX ) said Tuesday it has started a phase 2 trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with myasthenia gravis, a chronic autoimmune neuromuscular disease.

The company said the trial will enrol 120 patients. The primary endpoint of the study is defined as a more than 2-point increase in the Myasthenia Gravis Activities of Daily Living score from baseline or a myasthenic crisis requiring hospitalization, the company said.

The company also provided "positive" topline data from phase 1 of the study.

Phase 1 data showed consistent reductions from baseline across all myasthenia gravis outcome measures over time following treatment with subcutaneous BRIUMVI, TG Therapeutics ( TGTX ) said.

Shares of the company were up 2.5% in Tuesday's premarket activity.